Drug Trial Radar · NCT00487435
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
Last checked: Nov 19, 2026Latest source record: May 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,166
Actual
Start
Jun 2007
Primary completion
Jun 2009
Study completion Jun 2009
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Grünenthal GmbH
- First posted
- Jun 18, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the long-term safety profile of Tapentadol (CG5503) extended release (ER) at dosages ranging from 100 to 250 mg twice a day in treating patients with moderate to severe chronic pain over a period of 1 year. The study will also assess dosage requirements over the long term; characterize adverse events and tolerability, sleep quality, and potential symptoms of withdrawal; characterize pain intensity scores and overall impression of change; and characterize patient-related health outcomes.
Conditions
- Pain
- Osteoarthritis
- Low Back Pain
Interventions
Tapentadol (CG5503) Extended Release (ER)Drug
100, 150, 200, 250 mg oral tablet twice daily for 52 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Treatment-emergent Adverse Events (TEAE)Time frame: 52 weeks
Locations
148 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Hoover, Alabama
Site not named
Mobile, Alabama
Site not named
Mesa, Arizona
Site not named
Phoenix, Arizona
Site not named
Tempe, Arizona
Site not named
Tucson, Arizona
Site not named
Jonesboro, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Anaheim, California
Site not named
Carmichael, California
Site not named
Encinitas, California
Site not named
Fresno, California
Site not named
Huntington Park, California
Site not named
Laguna Hills, California
Site not named
Los Gatos, California
Site not named
Pico Rivera, California
Site not named
Pismo Beach, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
Upland, California
Site not named
Westlake Village, California
Site not named
Stamford, Connecticut
Site not named
Trumbull, Connecticut
Site not named
Chiefland, Florida
Site not named
Clearwater, Florida
Site not named
Fort Myers, Florida
Site not named
Hallandale, Florida
Site not named
Hollywood, Florida
Site not named
Jacksonville, Florida
Site not named
Kissimmee, Florida
Site not named
Miami, Florida
Site not named
New Port Richey, Florida
Site not named
Oldsmar, Florida
Site not named
Pembroke Pines, Florida
Site not named
Plantation, Florida
Site not named
Port Orange, Florida
Site not named
Sarasota, Florida
Site not named
Tamarac, Florida
Site not named
Tampa, Florida
Showing 40 of 148 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.